Fig. 3
IL-17 inhibits the production of CXCL9 family chemokines. a q-RT-PCR analyses of the indicated mRNAs in normal colon and colorectal tumor tissues of 5-month-old control (Il17ra+/−) and IL-17RA whole body knockout (Il17ra−/−) mice that also harbor Cdx2-Cre+/ApcF/+ genotypes (n = 12). b Colonic tumors from control (Il17ra+/−) and IL-17RA-deficient (Il17ra−/−) Cdx2-Cre+/ApcF/+ mice were cultured in Opti-MEM medium for 24 h. Concentrations of chemokines were tested using a bead-based immunoassay (Biolegend, for CXCL9), or plate based ELISA (R&D systems, for CXCL10). Data are shown as pg/ml chemokine per mg tumor in culture (n = 13). c 5-month-old Cdx2-Cre+/ApcF/+ mice were treated with i.p. injection of isotype or anti-IL-17A antibodies (100 μg per injection, every 3 days) for two weeks. Colonic tumors were harvested at the end of the study, and analyzed by q-RT-PCR for indicated mRNAs. n = 13. d Cdx2-Cre-ERT2+/ApcF/F mice (that were Il17ra−/− or Il17ra+/−) were sacrificed 5 weeks after tamoxifen-induced Apc ablation. Mouse MLN and tumors were subjected to q-RT-PCR analysis (n = 5 for MLN, 11 for tumor). Data represent means ± S.E.M. *p < 0.05 in Students’ t test